 Early Termination of Clinical Trials
"Early Termination of Clinical Trials" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Earlier than planned termination of clinical trials.
| Descriptor ID |
D057239
|
| MeSH Number(s) |
E05.581.500.400 N04.761.559.590.800.379 N05.715.360.575.575.800.379
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Early Termination of Clinical Trials".
Below are MeSH descriptors whose meaning is more specific than "Early Termination of Clinical Trials".
This graph shows the total number of publications written about "Early Termination of Clinical Trials" by people in this website by year, and whether "Early Termination of Clinical Trials" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 | | 2014 | 0 | 4 | 4 | | 2015 | 1 | 0 | 1 | | 2017 | 0 | 2 | 2 | | 2018 | 1 | 0 | 1 | | 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Early Termination of Clinical Trials" by people in Profiles.
-
Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E175-E179.
-
Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021 03 02; 325(9):833-842.
-
Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O'Donoghue ML. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.
-
Rogers RK, Hiatt WR, Patel MR, Shishehbor MH, White R, Khan ND, Bhalla NP, Jones WS, Low Wang CC. Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. Vasc Med. 2018 12; 23(6):513-522.
-
Geoerger B, Bergeron C, Gore L, Sender L, Dunkel IJ, Herzog C, Brochez L, Cruz O, Nysom K, Berghorn E, Simsek B, Shen J, Pappo A. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017 11; 86:358-363.
-
McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, Chan CL, Stafford D, Abuzzahab MJ, Viskochil D, Barlow SE, Angulo M, Myers SE, Whitman BY, Styne D, Roof E, Dykens EM, Scheimann AO, Malloy J, Zhuang D, Taylor K, Hughes TE, Kim DD, Butler MG. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017 12; 19(12):1751-1761.
-
Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu CH, Chow SH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez EM, Alberts DS, Lance P. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. J Natl Cancer Inst. 2016 12; 108(12).
-
Combs CA, Garite TJ, Maurel K, Abril D, Das A, Clewell W, Heyborne K, How H, Huang W, Lewis D, Lu G, Miller H, Nageotte M, Porreco R, Sheikh A, Tran L. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2015 Sep; 213(3):364.e1-12.
-
Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. Am Heart J. 2015 Jul; 170(1):117-22.
-
Hochster HS, Uboha N, Messersmith W, Gold PJ, ONeil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|